Latest Articles

Publication Date
Not Only Women Menstruate: Mice Now Have Periods—and It Could Redefine Reproductive Health - MSN

Not Only Women Menstruate: Mice Now Have Periods—and It Could Redefine Reproductive Health MSN

Published: Oct. 24, 2025, 5:25 p.m.
Shared Genetic Architecture Between Endometriosis and Psychiatric Conditions May Explain Comorbidity.

Endometriosis is a common chronic gynecological disorder with complex and poorly understood etiology and no definitive cure. Beyond pain and infertility, affected individuals frequently experience psychiatric comorbidities, often attributed to …

Published: Oct. 24, 2025, midnight
KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer - Indian Pharma Post

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer Indian Pharma Post

Published: Oct. 22, 2025, 5:03 p.m.
NSW women to benefit from next stage of Women's Health Package - Department of the Prime Minister and Cabinet

NSW women to benefit from next stage of Women's Health Package Department of the Prime Minister and Cabinet

Published: Oct. 22, 2025, noon
Not Only Women Menstruate: Mice Now Have Periods—and It Could Redefine Reproductive Health - The Daily Galaxy

Not Only Women Menstruate: Mice Now Have Periods—and It Could Redefine Reproductive Health The Daily Galaxy

Published: Oct. 22, 2025, 10:45 a.m.
NSW Women To Benefit From Next Stage Of Women's Health Package - Mirage News

NSW Women To Benefit From Next Stage Of Women's Health Package Mirage News

Published: Oct. 22, 2025, 12:27 a.m.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Addressing Meta-Inflammation in the Comprehensive Management of Chronic Pain.

Chronic pain is a widespread condition affecting millions globally, placing significant strain on healthcare systems, as evidenced by the current opioid crisis. Despite advances in pain management, conventional treatments often …

Published: Oct. 18, 2025, midnight
Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients - Labroots

Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients Labroots

Published: Oct. 16, 2025, 10 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!